N-(2-aminocyclohexyl)-4-methylbenzenesulfonamide | 499205-31-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-aminocyclohexyl)-4-methylbenzenesulfonamide
• 英文别名: N-(2-Aminocyclohexyl)-p-toluolsulfonamid；(1R,2R)-N-(2-amino-cyclohexyl)-4-methyl-benzenesulphonamide；N-(p-toluenesulfonyl)-(R,R)-1,2-diaminocyclohexane；N-(2-aminocyclohexyl)-p-toluene-sulfonamide；N-monotosyl-1,2-diaminocyclohexane
• CAS: 499205-31-1
• 化学式: C₁₃H₂₀N₂O₂S
• 分子量: 268.38
• InChiKey: VVOFSHARRCJLLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 N-(2-aminocyclohexyl)-4-methylbenzenesulfonamide 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以88.1%的产率得到N-(p-toluenesulfonyl)-N'-(Boc)-(R,R)-1,2-diaminocyclohexane
  参考文献：
  名称：

  Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands

  摘要：

  本发明涉及复合物的生物共轭物，所述复合物由公式1表示：其中，R，R′，R1，R′1，R2，R′2，R3，R′3，R4，R′4，R5，R′5，R6，R′6，R7，R′7，R8，R′8，R9，R′9，M，X，Y，Z和n的定义如本文所述，用作诊断成像中的对比剂。

  公开号：

  US20040057904A1
• 作为产物：
  描述：

  1,2-二氨基环己烷 、 对甲苯磺酰氯 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 N-(2-aminocyclohexyl)-4-methylbenzenesulfonamide
  参考文献：
  名称：

  A modular approach to trans-chelating, N-heterocyclic carbene ligand complexes

  摘要：

  The N-methyl bis-imidazolium salts 3 were converted to the silver carbenes 7, then reacted to give palladium(II) complexes 4 with trans-chelating, bidentate bis-imidazolylidine ligands. The similar salts 8, that do not have N-methyl substituents, gave the tetradentate complexes 9 in direct reactions with palladium chloride. The potential of these complexes for asymmetric catalysis is discussed. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(02)00535-9

文献信息

• Organic metal compound and process for preparing optically-active alcohols using the same
  申请人：Miki Takashi

  公开号：US20090062573A1

  公开（公告）日：2009-03-05

  The present invention provides an asymmetric reduction catalyst effective in preparing optically-active alcohol compounds having various functional groups, and a process for preparing optically-active alcohol compounds using said asymmetric reduction catalyst. The organic metal compound of the present invention is represented by the following general formula (1): wherein R 1 and R 2 may be mutually identical or different, and are an alkyl group, a phenyl group, a naphthyl group, a cycloalkyl group, or an alicyclic ring formed by binding R 1 and R 2 , which may have a substituent; R 3 is a hydrogen atom or an alkyl group; Cp is a cyclopentadienyl group, which may have a substituent, bound to M 1 via a π bond; X 1 is a halogen atom or a hydrido group; M 1 is rhodium or iridium; and * denotes asymmetric carbon.

  本发明提供了一种在制备具有各种官能团的光学活性醇化合物中有效的非对称还原催化剂，以及使用所述非对称还原催化剂制备光学活性醇化合物的方法。 本发明的有机金属化合物由以下通式(1)表示： 其中R1和R2可以相互相同或不同，并且是烷基、苯基、萘基、环烷基或由R1和R2结合形成的脂肪环环，其中可能含有取代基；R3是氢原子或烷基；Cp是环戊二烯基，可能含有取代基，通过π键与M1结合；X1是卤素原子或氢化物基团；M1是铑或铱；*表示不对称碳。
• [EN] PROCESS FOR THE PREPARATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN AGONISTE DU RÉCEPTEUR DE LA SPHINGOSINE-1-PHOSPHATE
  申请人：QUIM SINTETICA S A

  公开号：WO2020064818A1

  公开（公告）日：2020-04-02

  Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process.

  描述了用于制备奥扎尼莫德的工业可行且有利的工艺。该发明还披露了在该过程中获得的中间体。
• PROCESS FOR PRODUCING OPTICALLY ACTIVE ALCOHOL
  申请人：Hatakeyama Taito

  公开号：US20110282077A1

  公开（公告）日：2011-11-17

  The object of the present invention is to solve the problems in the prior arts, and to find more improved reaction conditions for suppressing the racemization of the product and obtaining an optically active alcohol at a high optical purity. The inventors achieved to solve the above problems by using a solvent system that is capable of resolving both an asymmetric catalyst and a formate salt, allowing the hydrogen source and the asymmetric catalyst to be present in the same phase.

  本发明的目的是解决先前技术中的问题，并找到更改进的反应条件，以抑制产物的消旋化并获得高光学纯度的光学活性醇。发明者通过使用一种能够分离不对称催化剂和甲酸盐的溶剂系统，使氢源和不对称催化剂能够存在于同一相中，从而解决了上述问题。
• [EN] METHOD FOR PRODUCING OPTICALLY ACTIVE beta-HYDROXY-alpha-AMINOCARBOXYLIC ACID ESTER<br/>[FR] PROCÉDÉ DE PRODUCTION D'UN ESTER D'ACIDE Beta-HYDROXY-Alpha-AMINOCARBOXYLIQUE OPTIQUEMENT ACTIF
  申请人：TAKASAGO PERFUMERY CO LTD

  公开号：WO2013065867A1

  公开（公告）日：2013-05-10

  The present invention relates to a novel method for producing an optically active β-hydroxy-α-aminocarboxylic acid ester, the method comprising performing an asymmetric reduction reaction of a β-keto-α-aminocarboxylic acid ester by use of a ruthenium complex as a catalyst.

  本发明涉及一种生产光学活性β-羟基-α-氨基羧酸酯的新方法，该方法包括利用钌配合物作为催化剂对β-酮-α-氨基羧酸酯进行不对称还原反应。
• [EN] PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS<br/>[FR] PROCÉDÉ DE FABRICATION DE COMPOSÉS CYCLOPENTYLPYRIMIDINES HYDROXYLÉES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2013173736A1

  公开（公告）日：2013-11-21

  The invention provides new processes for making and purifying hydroxylated cyclopenta[d]pyrimidine compounds, which are useful for the treatment of diseases such as cancer as AKT protein kinase inhibitors, including the compound (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one.

  这项发明提供了制备和纯化羟基化环戊[ｄ]嘧啶化合物的新工艺，这些化合物可用于治疗癌症等疾病作为AKT蛋白激酶抑制剂，包括化合物(S)-2-(4-氯苯基)-1-(4-((5R,7R)-7-羟基-5-甲基-6,7-二氢-5H-环戊[ｄ]嘧啶-4-基)哌嗪-1-基)-3-(异丙氨基)丙酮。